There are studies that show that an AGE breaker like ALT-711 (Alagebrium) might be useful in treating atherosclerosis, most particularly in diabetics.
Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis.
http://www.ncbi.nlm....pubmed/15220206
The advanced glycation end product-lowering agent ALT-711 is a low-affinity inhibitor of thiamine diphosphokinase.
https://www.research...c_Heart_Failure
The effect noticed seems to be a reduction in arterial stiffness, which makes lots of sense given the proposed effect of breaking AGE crosslinks. However, this seems to me to be a separate thing to reversing arterial plaques.
Does anyone believe that AGE breakers like ALT-711 have a role in reversing arterial plaques and if so is there evidence to back that up?
Equally importantly, does anyone have any concern that a patient using ALT-711 with existing established arterial plaques might destabilize them, leading to plaque rupture?
Edited by Daniel Cooper, 17 March 2016 - 07:39 PM.